ClinicalTrials.gg
RecruitingNCT07028658SCEDuLLUpdated Apr 3, 2026

Effectiveness of Speech Therapy for Lip-reading in Patients With Hearing Aids: SCED Study

An observational study in Hearing Loss, Bilateral or Unilateral, sponsored by Institut Pasteur. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Institut Pasteur · Observational

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
8
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to investigate whether lip reading rehabilitation improves viseme recognition in individuals with hearing impairments who use hearing aids.

02

Conditions studied

  • Hearing Loss, Bilateral or Unilateral

Browse trials for

03

In context

Hearing Loss

796 studies on the registry are indexed under Hearing Loss; 193 are open to participants now.

This study's planned enrollment of 8 is below the median of 100 across 192 observational studies indexed under Hearing Loss.

Browse Hearing Loss studies →

Lead sponsor

Institut Pasteur is the lead sponsor of 99 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of hearing-impaired individuals with hearing aids

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 18 or older
  • Affiliated with a social security system
  • Moderate to severe bilateral post-lingual hearing loss, fitted with hearing aids for more than 6 months
  • Wearing hearing aids for a minimum of 8 hours/day on average over the past month
  • Intelligibility in quiet > 80% correct responses at 60 dB (Lafon cochlear list)
  • Difficulty in noisy environments rated > 6 on a 0-10 EVA scale
  • French language comprehension level of at least B1 CEFR (Common European Framework of Reference for Languages)
  • Willing to participate in speech therapy rehabilitation at a rate of 2 sessions per week

Exclusion criteria

Exclusion Criteria:

  • Patient who has already undergone speech therapy rehabilitation as part of their hearing loss treatment
  • Diagnosis of neurodegenerative disease or history of brain injury (traumatic brain injury, stroke, tumor, meningitis, etc.)
  • Uncorrected vision or visual impairment affecting lip reading (e.g. AMD, glaucoma, unoperated cataract, etc.)
  • Presence of severe tinnitus (score > 56) on the Tinnitus Handicap Inventory (THI) questionnaire
  • Significant cognitive impairment (CODEX C or D) or (MOCA) score \< 23
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
8 participants (estimated)
Patient registry
No

Interventions

  • OtherSpeechreading training

    The patient will undergo 16 lip reading training sessions. By developing functional lip reading skills, they will be able to fill in the gaps in auditory information they miss, especially in loud or noisy settings

06

What researchers measure

Primary outcomes

  1. Repetition score, in words (with and without labial doppelganger) of Lafon's cochlear lists presented on video support in visual-only modality

    Time frame: 26 sessions (4,5 months)

  2. Repetition score, in visemes (with and without labial doppelganger) of Lafon's cochlear lists presented on video support in visual-only modality

    Time frame: 26 sessions (4,5 months)

Secondary outcomes

  1. Repetition score of 10 non-words on recorded support with a Signal-to-Noise Ratio of 10

    Time frame: 26 sessions (4,5 months)

  2. Repetition score of sentences on video support in audiovisual modality

    Time frame: 26 sessions (4,5 months)

  3. Identification score of two sequences of musical notes

    Time frame: 26 sessions (4,5 months)

  4. Impact of speech therapy rehabilitation on quality of life

    AVS from 0 to 10

    Time frame: 26 sessions (4,5 months)

07

Study locations

1 of 1 sites recruiting
  • Cabinet d'orthophonie
    Paris, 75008, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2026, 11 months after the start.

Of 98 observational studies under Hearing Loss, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 83. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jun 19, 2025
StartActual
Oct 16, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07028658
Lead sponsor
Institut Pasteur
Collaborators
IHU reConnect
Responsible party
Sponsor
First posted
Jun 19, 2025
Start date
Oct 16, 2025
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Apr 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion